FDA advisors unanimously reject Intarcia ' s embattled type 2 diabetes treatment

I2o Ther­a­peu­tics CEO Kurt Graves set out on Thurs­day to make a case to a pan­el of the FDA’s ex­pert ad­vi­sors that the ben­e­fits of his com­pa­ny’s twice-re­ject­ed im­plant to treat type 2 di­a­betes out­weigh its risks — but the com­mit­tee wasn’t con­vinced. The FDA’s En­docrino­log­ic…#kurtgraves #fda #2diabetes #metabolic #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news